EICHOR
● Active Not Recruiting
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Condition: Urinary Bladder Neoplasms · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease; and disease-free survival (DFS) in participants treated with TAR-200 alone with papillary disease only (Cohort 4).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (144)
| Del Sol Research Management, LLC | Tucson, Arizona, United States | — |
| University of Southern California | Los Angeles, California, United States | — |
| Genesis Healthcare Partners - Genesis Research Greater Los Angeles | Sherman Oaks, California, United States | — |
| The Urology Center of Colorado | Denver, Colorado, United States | — |
| Foothills Urology - Golden Off | Golden, Colorado, United States | — |
| DuPage Medical Group | Lisle, Illinois, United States | — |
| Urology of Indiana | Greenwood, Indiana, United States | — |
| Wichita Urology Group | Wichita, Kansas, United States | — |
| Michigan Institute of Urology | Troy, Michigan, United States | — |
| NYU Langone Health | New York, New York, United States | — |
| SUNY Upstate Medical University | Syracuse, New York, United States | — |
| Associated Medical Professionals | Syracuse, New York, United States | — |
+ 132 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.